<DOC>
	<DOCNO>NCT00107770</DOCNO>
	<brief_summary>The purpose study evaluate safety sodium phenylbutyrate ( NaPB ) treatment subject amyotrophic lateral sclerosis ( ALS ) ability take medication without major side effect .</brief_summary>
	<brief_title>Safety Study Oral Sodium Phenylbutyrate Subjects With ALS ( Amyotrophic Lateral Sclerosis )</brief_title>
	<detailed_description>Although know nerve cell die brain spinal cord patient ALS , cause cell death unknown . There evidence cell death may cause change DNA , body 's genetic material . Drugs sodium phenylbutyrate ( NaPB ) increase expression gene , block motor nerve cell ALS die , may prove effective therapy ALS . NaPB show improvement survival mouse condition similar ALS . STUDY DESIGN : All research participant take sodium phenylbutyrate total 20 week . The dose medication increase every 2 4 week maximum , easily tolerate dose achieve ( study maximum 21 g/day ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Diagnosed ALS At least 18 year age Women , become pregnant , must actively use effective birth control measure Must neurological ( nervous system ) disease Veterans eligible participate VA sit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>ALS</keyword>
	<keyword>histone deacetylase inhibition</keyword>
	<keyword>open label</keyword>
	<keyword>safety study</keyword>
	<keyword>sodium phenylbutyrate</keyword>
</DOC>